Nolc1-KO Mouse
Common Name
Nolc1-KO
제품 ID
S-KO-17035
Backgroud
C57BL/6JCya
품종 계통계통 ID
KOCMP-70769-Nolc1-B6J-VB
상태
이 마우스 계통을 논문에서 사용할 경우, “Nolc1-KO Mouse (카탈로그 번호 S-KO-17035)은 Cyagen에서 구입하였습니다.”라고 명시해 주시기 바랍니다.
구매 가능한 제품 종류
연령
Genotype
성별
수량
표준 제공 조건은 최소 3마리의 이형접합(heterozygous) 보균자를 보장합니다. 동형접합(homozygous) 보균자 및/또는 특정 성별에 대한 브리딩 서비스도 제공됩니다.
기본 정보
품종 계통
Nolc1-KO
품종 계통계통 ID
KOCMP-70769-Nolc1-B6J-VB
유전자명
제품 ID
S-KO-17035
유전자 별칭
P130, NOPP130, NOPP140
배경
C57BL/6JCya
NCBI ID
변형 내용
Conventional knockout
염색체
Chr 19
Phenotype
Datasheet
적용 분야
--
품종 계통 설명
Ensembl 전사체 ID
ENSMUST00000165017
NCBI 전사체 ID
NM_001039352.2
타겟 영역
Exon 2~5
유효 영역 크기
~1383 bp
유전자 연구 개요
Nolc1, also known as Nucleolar and coiled-body phosphoprotein 1, is a nucleolar protein. It is responsible for nucleolus construction and ribosomal RNA (rRNA) synthesis, and acts as a chaperone shuttling between the nucleolus and cytoplasm. Nolc1 participates in multiple cellular life activities such as ribosome biosynthesis, DNA replication, transcription regulation, RNA processing, cell cycle regulation, apoptosis, and cell regeneration [1].
In cancer research, Nolc1 knockdown suppresses prostate cancer progressions by reducing AKT phosphorylation and β-catenin accumulation, indicating its role in promoting prostate cancer progression [2]. The Pten-NOLC1 fusion gene promotes cancers involving MET and EGFR signalings, acting as a driver for human cancers [3]. In endometrial cancer, NOLC1 is highly expressed in paclitaxel-resistant cells, and the SPOP/NOLC1/B4GALT1 signaling axis enhances paclitaxel resistance by inducing O-dysglycosylation [4]. In epithelial ovarian cancer, circ-NOLC1, which is derived from Nolc1, promotes tumorigenesis and progression by binding ESRP1 and modulating CDK1 and RhoA expression [5]. In colorectal cancer, high expression of NOLC1 is an independent prognostic factor for survival, enhancing cell proliferation and migration [6]. In esophageal carcinoma, NOLC1 overexpression is associated with poor prognosis, and knockdown of NOLC1 inhibits the PI3K-AKT pathway to improve the prognosis [8]. However, in thyroid cancer, Nolc1 is identified as a tumor suppressor gene [7].
In conclusion, Nolc1 is crucial for various cellular functions, especially in ribosome-related processes. Through gene-knockdown or fusion-gene models in cancer research, its role in promoting or suppressing different cancers has been revealed. Understanding Nolc1 provides new perspectives for cancer diagnosis and therapeutic target selection.
References:
1. Zhai, Fengguang, Wang, Jie, Luo, Xia, Ye, Meng, Jin, Xiaofeng. 2023. Roles of NOLC1 in cancers and viral infection. In Journal of cancer research and clinical oncology, 149, 10593-10608. doi:10.1007/s00432-023-04934-5. https://pubmed.ncbi.nlm.nih.gov/37296317/
2. Kim, Wansoo, Yeo, Dong-Yeop, Choi, Seong-Kyoon, Park, Jin-Kyu, Park, Song. 2022. NOLC1 knockdown suppresses prostate cancer progressions by reducing AKT phosphorylation and β-catenin accumulation. In Biochemical and biophysical research communications, 635, 99-107. doi:10.1016/j.bbrc.2022.10.038. https://pubmed.ncbi.nlm.nih.gov/36265288/
3. Luo, Jian-Hua, Liu, Silvia, Tao, Junyan, Tseng, George, Yu, Yan-Ping. 2020. Pten-NOLC1 fusion promotes cancers involving MET and EGFR signalings. In Oncogene, 40, 1064-1076. doi:10.1038/s41388-020-01582-8. https://pubmed.ncbi.nlm.nih.gov/33323972/
4. Zhai, Fengguang, Li, Yuxuan, Zheng, Jingfei, Ye, Meng, Jin, Xiaofeng. 2025. SPOP/NOLC1/B4GALT1 signaling axis enhances paclitaxel resistance in endometrial cancer by inducing O-dysglycosylation. In Oncogene, , . doi:10.1038/s41388-025-03347-7. https://pubmed.ncbi.nlm.nih.gov/40097806/
5. Chen, Shuo, Wu, Wu, Li, Qian-Hui, Wei, Xiao-Qing, Zhao, Yang. 2021. Circ-NOLC1 promotes epithelial ovarian cancer tumorigenesis and progression by binding ESRP1 and modulating CDK1 and RhoA expression. In Cell death discovery, 7, 22. doi:10.1038/s41420-020-00381-0. https://pubmed.ncbi.nlm.nih.gov/33483472/
6. Sun, Zhiwei, Zhang, Qianshi, Lv, Jinjuan, Zuo, Yun-Fei, Ren, Shuang-Yi. 2023. High expression of NOLC1 as an independent prognostic factor for survival in patients with colorectal cancer. In Journal of cancer research and clinical oncology, 149, 15697-15712. doi:10.1007/s00432-023-05297-7. https://pubmed.ncbi.nlm.nih.gov/37670166/
7. Zhai, Fengguang, Li, Yuxuan, Luo, Xia, Jin, Xiaofeng, Ye, Meng. 2024. NOLC1 was identified as a tumor suppressor gene in thyroid cancer and correlated with prognosis by bioinformatics. In American journal of cancer research, 14, 2055-2071. doi:10.62347/IYVV7581. https://pubmed.ncbi.nlm.nih.gov/38859850/
8. Kong, Fanguo, Shang, Yansheng, Diao, Xingyuan, Huang, Jiaguo, Liu, Hui. 2021. Knockdown of NOLC1 Inhibits PI3K-AKT Pathway to Improve the Poor Prognosis of Esophageal Carcinoma. In Journal of oncology, 2021, 9944132. doi:10.1155/2021/9944132. https://pubmed.ncbi.nlm.nih.gov/34046062/
품질 관리 기준
정자 검사
동결 보존 전: 정자 농도 측정 및 정자 생존율 평가.
동결 보존 후: 각 배치에서 동결 보존된 정자 바이알 1개를 선택하여 체외수정(in vitro fertilization)에 사용합니다.
Environmental Standards:
SPFAvailable Region:
GlobalSource:
Cyagen문의하기
맞춤형 동물 모델 관련 상담을 위해 Cyagen 전문가와 연락해 보세요. 아래 양식을 작성하여 상담을 시작하거나 견적을 요청하시기 바랍니다.
Cyagen은 고객님의 개인정보를 소중히 여깁니다. 최신 제품, 서비스 및 인사이트를 안내드리고자 합니다. 고객님의 수신 설정은 다음과 같습니다:
해당 커뮤니케이션은 언제든지 수신 거부하실 수 있습니다. 수신 거부 방법 및 데이터 보호에 대한 자세한 내용은 개인정보처리방침을 참고해 주시기 바랍니다.
아래 버튼을 클릭함으로써, 요청하신 콘텐츠 제공을 위해 본 양식을 통해 제출된 개인정보를 Cyagen이 저장 및 처리하는 데 동의하게 됩니다.